Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice

International Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 279-285

  Sasaki, Akira ^a   Kitamura, Kazuyuki ^b   Alcalde, Rafael E ^a   Tanaka, Toshimitsu ^b   Suzuki, Atushi ^a   Etoh, Yohei ^a   Matsumura, Tomohiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

[1 HYDROXY 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHYLIDENE]BISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOLYSIS;

EID: 0031806712     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6     Document Type: Article

References (21)

1. AVERBUCH, S.D., New bisphosphonates in the treatment of bone metastases. Cancer (suppl.), 72, 3443-3452 (1993).
2. BODY, J.J., Metastatic bone disease: clinical and therapeutic aspects. Bone, 13, S57-S62 (1992).
3. BOISSIER, S., MAGNETTO, S., FRAPPART, L., CUZIN, B., EBETINO, F.H., DELMAS, P.D. and CLEZARDIN, P., Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res., 57, 3890-3894 (1997).
4. CARANO, A., TEITELBAUM, S.L., KONSEK, J.D., SCHLESINGER, P.H. and BLAIR, H.C., Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. clin. Invest., 85, 456-461 (1990).
5. FLEISCH, H., Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs, 42, 919-944 (1991).
6. GALASKO, C.S.B., Mechanisms of bone destruction in the development of skeletal metastases. Nature (Lond.), 263, 507-508 (1976).
7. HUGHES, D.E., WRIGHT, K.R., UY, H.L., SASAKI, A., YONEDA, T., ROODMAN, G.D., MUNDY, G.R. and BOYCE, B.F., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res., 10, 1478-1487 (1995).
8. KOSTENUIK, P.J., ORR, F.W., SUYAMA, K. and SINGH, G., Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res., 53, 5452-5457 (1993).
9. 2MBP. Cancer, 72, 91-98 (1993).
10. MUNDY, G.R., Mechanisms of osteolytic bone destruction. Bone, 12, S1-S6 (1991).
11. MURAKAMI, H., TAKAHASHI, N., SASAKI, T., UDAGAWA, N., TANAKA, S., NAKAMURA, I., ZHANG, D., BARBIER, A. and SUDA, T., A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone, 17, 137-144 (1995).
12. POWELL, N., Metastatic carcinoma in association with Paget's disease of bone. Brit. J. Radiol., 56, 582-585 (1983).
13. SAHNI, M., GUENTHER, H.L., FLEISCH, H., COLLIN, P. and MARTIN, T.J., Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. clin. Invest., 91, 2004-2011 (1993).
14. SASAKI, A., BOYCE, B.F., STORY, B., WRIGHT, K.R., CHAPMAN, M., BOYCE, R., MUNDY, G.R. and YONEDA, T., Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 55, 3551-3557 (1995).
15. SASAKI, A., WILLIAMS, P.J., MUNDY, G.R. and YONEDA, T., Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. J. Bone Miner. Res., 9, S294 (1994).
16. SATO, M., GRASSER, W., ENDO, N., AKINS, R., SIMMONS, H., THOMPSON, D.D., GOLUB, E. and RODAN, G.A., Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. clin. Invest., 88, 2095-2105 (1991).
17. SCHMIDT, A., RUTLEDGE, S.J., ENDO, N., OPAS, E.E., TANAKA, H., WESOLOWSKI, G., LEU, C.T., HUANG, Z., RAMACHANDARAN, C., RODAN, S.B. and RODAN, G.A., Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. natl Acad. Sci. (Wash.), 93, 3068-3073 (1996).
18. VAN BEEK, E., HOEKSTRA, M., VAN DE RUIT, M., LOWIK, C. and PAPAPOULOS, S., Structural requirements for bisphosphonate actions in vitro. J. Bone Miner. Res., 9, 1875-1882 (1994).
19. VAN HOLTEN-VERZANTVOORT, A.T., BIJVOET, O.L.M., CLETON, F.J., HERMANS, J., KROON, H.M., HARINCK, H.I.J., VERMEY, P., ELTE, J.W.F., NEIJT, J.P., BEEX, L.V.A.M. and BLIJHAM, G., Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet, 31, 983-985 (1987).
20. WILLIAMS, D.A., The comparison of several dose levels with a zero dose control. Biometrics, 28, 519-531 (1972).
21. YONEDA, T., SASAKI, A., DUNSTAN, C., WILLIAMS, P.J., BAUSS, F., DE CLERCK, Y.A. and MUNDY, G.R., Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase - 2. J. clin. Invest., 99, 2509-2517 (1997).